We’re putting the finishing touches on something special — ordering opens soon. Stay tuned.
← Back to Catalog

Sermorelin

Sermorelin vial frontSermorelin vial back
Loading...

Summary

GHRH(1-29), GRF(1-29)

Sermorelin is a peptide that signals the pituitary gland to release growth hormone in a natural pulsatile pattern. It stimulates growth hormone secretion through GHRH receptor activation while maintaining the body's normal feedback regulation. The compound was originally developed and FDA-approved in 1997 for diagnostic testing of growth hormone secretion.

Current Research
  • Growth hormone release via GHRH receptor
  • Hormonal health and healthy-aging research
  • Sleep quality and recovery
Identification
CAS
86168-78-7
Formula
C183H294N55O59S
M.W.
3358 g/mol

Key Research Statistics

Growth Hormone Releasing Hormone Analog

FDAPreviously Approved (Geref)30+ years of clinical history — withdrawn for commercial, not safety reasons
25–30%IGF-1 ElevationWithin 2 weeks of onset — sustained through 12 weeks
GH Elevation
Alone vs stacked with Ipamorelin
Sermorelin + Ipamorelin400% of baseline
Sermorelin Alone250% of baseline
Ipamorelin Alone150% of baseline
Clinical endocrinology data
Body Composition (6-Month Studies)
Deep Sleep ↑50%
Fat Mass ↓4%
Lean Mass ↑3%
Growth hormone therapy studies
5/ 5
Evidence Rating
FDA-approved compound, 30+ year clinical history, multiple RCTs
Literature review

Need-to-Know

  • Room Temperature (Lyophilized): 4-8 weeks
  • Refrigerated (Reconstituted): Up to 90 days
  • Frozen (Lyophilized): 24+ months
  • Reconstitution Solution: Bacteriostatic water
  • Appearance: White powder

Regulatory Status

Not FDA-approvedWithdrawnResearch

Previously FDA-approved for diagnostic use. Marketing approval withdrawn in 2012.

Sources: FDA.gov

History

1970s
Discovered in 1970s as synthetic growth hormone releaser.
1980s
FDA granted special status for childhood growth disorders (1988).
1990s
FDA approved for testing (1990) and treatment (1997) of growth problems in kids.
2000s
Discontinued in 2008 due to manufacturing issues, not safety.
2010s
No longer available as approved drug; made by compounding pharmacies.
2020s
Still used off-label through compounders.

3D Structure

37-amino-acid peptide · 3358 g/mol

Interactive model
Sermorelin molecule previewExplore 3D Structure

Sermorelin at the Cellular Level

GHRH analog

Mechanism
Sermorelin cellular mechanism preview

Sermorelin in the Body

GHRH analog (1-29 fragment)

Hormonal
Sermorelin in the Body

Research Library

Peer-reviewed studies

From Published Literature

"Sermorelin acts as a growth hormone-releasing hormone analogue, stimulating the pituitary gland to preserve natural pulsatile growth hormone secretion."

Richard F. WalkerClinical Interventions in Aging
Verify on PubMed

Complete Your Protocol

Complementary compounds from other research areas